FMO2<sup>+</sup> cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma
We identified a novel FMO2<sup>+</sup> CAF subset that serves as a critical regulator of microenvironmental immune properties and a predictive biomarker of the immunotherapy response in patients with HCC. CCL19 in combination with anti-PD-1 therapy may constitute a novel therapeutic strategy for HCC.
Authors
- Hui‐Chuan Sun (ORCID: https://orcid.org/0000-0003-3761-7058)
- Jialei Weng (ORCID: https://orcid.org/0000-0002-4916-0799)
- Wenxin Xu (ORCID: https://orcid.org/0000-0002-8964-4341)
- Qing‐Hai Ye (ORCID: https://orcid.org/0000-0002-6724-4435)
- Yufei Zhao (ORCID: https://orcid.org/0000-0002-5919-7595)
- Peiyi Xie (ORCID: https://orcid.org/0000-0001-5130-1506)
- Shaoqing Liu (ORCID: https://orcid.org/0000-0002-6790-9521)
- Ying-Hao Shen (ORCID: https://orcid.org/0000-0002-3014-9338)
- Minghao Xu (ORCID: https://orcid.org/0000-0003-0535-8231)
- Hui Li (ORCID: https://orcid.org/0000-0002-8537-2174)
- Junbo Chen (ORCID: https://orcid.org/0000-0002-1623-6339)
- Qiang Yu (ORCID: https://orcid.org/0009-0009-8474-8510)
- Mincheng Yu (ORCID: https://orcid.org/0000-0001-9998-5708)
- Bruce T. Liang (ORCID: https://orcid.org/0000-0002-4444-387X)
Institutions
- Fudan University (CN)
- Zhongshan Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1136/jitc-2025-011648
- Citations
- 8
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 5.39
Funders
- National Natural Science Foundation of China
- Ministry of Science and Technology of the People's Republic of China
- China Postdoctoral Science Foundation